FDX
Proxy season, but make it spicy
FedEx is getting a little more than the usual “please approve the board” treatment this year. IWP Capital, a faith-based co-filer, says it’ll vote FOR Proposal 6 on the company’s 2026 proxy statement, which calls for a board-level risk report tied to abortion-drug distribution.
The backdrop here is legal mush: enforcement of the Comstock Act is still unsettled, which means companies touching the mailstream don’t get a neat little rulebook stamped good to go. Instead, they get uncertainty — and uncertainty is corporate catnip for shareholder proposals.
Why investors should care
This isn’t about FedEx suddenly becoming a policy think tank. It’s about the company’s exposure to:
- reputational blowback from contentious shipments,
- potential compliance costs if the legal landscape shifts,
- and the very real chance that governance fights start eating up management attention.
For a company that makes money moving other people’s stuff, the question is pretty simple: what happens when the stuff itself becomes the headline?
Big picture
The vote lands at the annual meeting on September 28, 2026. If the proposal gets traction, FedEx could be pushed to spell out how it thinks about this risk. If not, the issue probably just becomes one more reminder that even delivery giants can get pulled into culture-war turbulence.